MedTrace Logo

Effectiveness of Protein Supplementation on Frailty Improvement, Muscle Strength and Physical Performance Among Pre-Frail Elderly People

NCT05648617 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-05-23

No results posted yet for this study

Summary

The goal of this randomized clinical trial is to study the effectiveness of protein supplements in frailty improvement, muscle strength, physical performance, energy intake and body composition of pre-frail elderly people. in Selangor, Malaysia.

The main question\[s\] it aims to answer are:

Does PS intervention significantly affect in frailty improvement, muscle strength, physical performance, energy intake and body composition of elderly people? For the interventional group, Participants will receive 30g of SUSTINEX Hydrolyzed Whey Protein. The participants will be asked to add it to their food or drinks to reach the goal of consuming 30g daily. For control group, participants will receive no intervention- usual care, will receive the standard care of the clinic without supplemented with PS.

Conditions

Interventions

DIETARY_SUPPLEMENT

SUSTINEX Hydrolyzed Whey Protein

Participants will receive 30g of SUSTINEX Hydrolyzed Whey Protein. The participants will be asked to add it to = to reach the goal of consuming 30g daily. SUSTINEX Whey Protein Plus is an authorized protein supplement which is manufactured and made in Malaysia by Nova Laboratories Sdn. Bhd. (179832-D). It consists of whey protein isolate and whey protein hydrolyze to achieve sufficient protein requirement.

Sponsors & Collaborators

  • Universiti Putra Malaysia

    lead OTHER

Principal Investigators

  • Associate Professor Dr Siti Nur 'Asyura B Adznam, Ass.prof · University Putra Malaysia

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-31
Primary Completion
2023-09-30
Completion
2023-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05648617 on ClinicalTrials.gov